{"id":"glivec","rwe":[],"tags":[],"trials":[],"_chembl":{"chemblId":"CHEMBL1642","moleculeType":"Small molecule","molecularWeight":"589.72"},"aliases":["Mesylate Imatinib tablet"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Glivec","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:18:04.695150+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Glivec","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:18:11.893866+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:18:10.252109+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Glivec","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:18:10.845279+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bcr/Abl fusion protein inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:18:11.893826+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1642/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:18:11.558181+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"_scrapedAt":"2026-03-27T23:31:14.376Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Imatinib","title":"Imatinib","extract":"Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used to treat cancer. Imatinib is a small molecule inhibitor targeting multiple tyrosine kinases such as CSF1R, ABL, c-KIT, FLT3, and PDGFR-β. Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome–positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome."},"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:18:13.161048+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT07493408","phase":"PHASE2","title":"Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-30","conditions":"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia, Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)","enrollment":45},{"nctId":"NCT04394416","phase":"PHASE3","title":"Trial of Imatinib for Hospitalized Adults With COVID-19","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2020-06-02","conditions":"COVID-19","enrollment":21},{"nctId":"NCT07171203","phase":"PHASE1","title":"Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-06","conditions":"Gastrointestinal Stromal Tumors","enrollment":18},{"nctId":"NCT05143840","phase":"PHASE2","title":"Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"RECRUITING","sponsor":"Augusta University","startDate":"2022-04-22","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid","enrollment":100},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT00070499","phase":"PHASE2","title":"Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-08-15","conditions":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","enrollment":406},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT00044304","phase":"PHASE2","title":"Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-09-26","conditions":"Eosinophilic Myeloid Neoplasm, Hypereosinophilic Syndrome","enrollment":70},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT00421317","phase":"PHASE2","title":"Imatinib in Adult Patients With Metastatic Ocular Melanoma","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2005-12","conditions":"Melanoma","enrollment":13},{"nctId":"NCT01046487","phase":"PHASE1","title":"Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2009-02-09","conditions":"Cancer","enrollment":26},{"nctId":"NCT04971226","phase":"PHASE3","title":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-06","conditions":"Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive","enrollment":406},{"nctId":"NCT01746836","phase":"PHASE2","title":"Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-01-17","conditions":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":50},{"nctId":"NCT04877522","phase":"PHASE4","title":"Asciminib Roll-over Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-08-30","conditions":"Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive","enrollment":347},{"nctId":"NCT05306301","phase":"PHASE2","title":"Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2022-10-05","conditions":"Chemotherapy, Leukemia, Acute Lymphoblastic","enrollment":32},{"nctId":"NCT03516279","phase":"PHASE2","title":"Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-06-26","conditions":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease","enrollment":40},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT07413263","phase":"","title":"Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-05-01","conditions":"Chronic Myeloid Leukemia","enrollment":75},{"nctId":"NCT06090669","phase":"PHASE1","title":"Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-19","conditions":"Inherited Bone Marrow Failure Syndrome, Familial Platelet Disorder With Predisposition to Myeloid Malignancies","enrollment":75},{"nctId":"NCT05493215","phase":"PHASE2","title":"Imatinib TDM in GIST","status":"RECRUITING","sponsor":"Reema A. Patel","startDate":"2024-03-26","conditions":"Gastrointestinal Stromal Tumors","enrollment":28},{"nctId":"NCT07406633","phase":"PHASE2","title":"KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting","status":"NOT_YET_RECRUITING","sponsor":"Kumquat Biosciences Inc.","startDate":"2026-04","conditions":"GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer","enrollment":46},{"nctId":"NCT05381753","phase":"","title":"Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World","status":"COMPLETED","sponsor":"CStone Pharmaceuticals","startDate":"2022-08-29","conditions":"Gastrointestinal Stromal Tumors","enrollment":61},{"nctId":"NCT06655246","phase":"PHASE1","title":"A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2025-03-27","conditions":"Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm","enrollment":157},{"nctId":"NCT03673501","phase":"PHASE3","title":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2019-02-08","conditions":"Gastrointestinal Stromal Tumors","enrollment":453},{"nctId":"NCT01742299","phase":"PHASE4","title":"Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-26","conditions":"GIST and CML","enrollment":155},{"nctId":"NCT07218926","phase":"PHASE3","title":"A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-12-03","conditions":"Gastrointestinal Neoplasms","enrollment":450},{"nctId":"NCT03997903","phase":"PHASE1, PHASE2","title":"Imatinib for Pain in Sickle Cell Anemia","status":"TERMINATED","sponsor":"Indiana University","startDate":"2020-02-26","conditions":"Sickle Cell Disease","enrollment":7},{"nctId":"NCT03610971","phase":"PHASE2","title":"Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-19","conditions":"Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase","enrollment":24},{"nctId":"NCT06889168","phase":"PHASE1","title":"Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-10-20","conditions":"Lymphangioleiomyomatosis (LAM), Lymphangioleiomyomatosis","enrollment":20},{"nctId":"NCT05245968","phase":"PHASE1","title":"A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2021-12-01","conditions":"Gastrointestinal Stromal Tumors","enrollment":78},{"nctId":"NCT06087263","phase":"PHASE2","title":"Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-06-18","conditions":"Gastrointestinal Stromal Tumors","enrollment":3},{"nctId":"NCT05152472","phase":"PHASE2","title":"A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2022-01-14","conditions":"Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor","enrollment":110},{"nctId":"NCT02891395","phase":"PHASE2","title":"Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2012-12-24","conditions":"Graft Versus Host Disease","enrollment":65},{"nctId":"NCT04626024","phase":"PHASE2","title":"Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2020-12-22","conditions":"Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission","enrollment":100},{"nctId":"NCT03654768","phase":"PHASE2","title":"Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-10-24","conditions":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":81},{"nctId":"NCT05734105","phase":"PHASE3","title":"A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2023-12-13","conditions":"GIST","enrollment":54},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT06682169","phase":"PHASE3","title":"Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11-20","conditions":"Graft-versus-host Disease","enrollment":182},{"nctId":"NCT01991379","phase":"PHASE1, PHASE2","title":"MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-11","conditions":"Gastrointestinal Stromal Tumor (GIST)","enrollment":75},{"nctId":"NCT03589326","phase":"PHASE3","title":"A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2018-10-04","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)","enrollment":245},{"nctId":"NCT01771458","phase":"PHASE2","title":"A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2012-10","conditions":"Reccurent/Metastatic Solid Tumor Disease","enrollment":742},{"nctId":"NCT04070443","phase":"PHASE2","title":"Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Leon Berard","startDate":"2019-11-13","conditions":"Philadelphia Chromosome Positive CML, BCR-ABL Positive Chronic Myelogenous Leukemia","enrollment":170},{"nctId":"NCT05489237","phase":"PHASE1","title":"First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors","status":"RECRUITING","sponsor":"IDRx Inc. - A GSK Company","startDate":"2022-08-03","conditions":"Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease","enrollment":278},{"nctId":"NCT03578367","phase":"PHASE2","title":"Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-22","conditions":"CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic","enrollment":104},{"nctId":"NCT05623774","phase":"PHASE1","title":"A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg","status":"COMPLETED","sponsor":"Inhibikase Therapeutics","startDate":"2022-12-16","conditions":"CML","enrollment":64},{"nctId":"NCT00816114","phase":"","title":"Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-06-08","conditions":"Chronic Myelogenous Leukemia","enrollment":3000},{"nctId":"NCT01316250","phase":"NA","title":"Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2010-08","conditions":"Chronic Myelogenous Leukemia","enrollment":13},{"nctId":"NCT07188428","phase":"","title":"Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-27","conditions":"Leukemia, Chronic Myeloid","enrollment":2298},{"nctId":"NCT07022743","phase":"PHASE2","title":"Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Obafemi Awolowo University","startDate":"2025-07-01","conditions":"Chronic Myeloid Leukemia (CML)","enrollment":75},{"nctId":"NCT07158294","phase":"NA","title":"Identification of BCR::ABL1 Mutations by Digital PCR in CML","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2026-02-01","conditions":"Chronic Myeloid Leukemia (CML)","enrollment":150},{"nctId":"NCT07151820","phase":"","title":"A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-08","conditions":"Leukemia, Chronic Myeloid","enrollment":2546},{"nctId":"NCT05816785","phase":"EARLY_PHASE1","title":"Pilot Study of Imatinib Cetuximab Combo for H & N Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-04-18","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck","enrollment":15},{"nctId":"NCT04598009","phase":"PHASE2","title":"Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-03-03","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":25},{"nctId":"NCT01698905","phase":"PHASE2","title":"Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-20","conditions":"Chronic Myeloid Leukemia","enrollment":163},{"nctId":"NCT00777036","phase":"PHASE2","title":"A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-03-20","conditions":"Leukemia","enrollment":133},{"nctId":"NCT01347216","phase":"","title":"COMPERA / COMPERA-KIDS","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2007-07-01","conditions":"Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)","enrollment":14000},{"nctId":"NCT01907607","phase":"PHASE2","title":"Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2014-02","conditions":"Advanced Gastrointestinal Stromal Tumors","enrollment":29},{"nctId":"NCT00015847","phase":"PHASE2","title":"Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2001-04","conditions":"Leukemia","enrollment":25},{"nctId":"NCT00265798","phase":"PHASE2","title":"Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09-14","conditions":"Gastrointestinal Stromal Tumor","enrollment":38},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT05385549","phase":"PHASE2","title":"5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-09-07","conditions":"Gastrointestinal Stromal Tumors","enrollment":35},{"nctId":"NCT07096609","phase":"PHASE1, PHASE2","title":"Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-09-08","conditions":"GIST","enrollment":48},{"nctId":"NCT04838041","phase":"PHASE2","title":"Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-11-11","conditions":"Chronic Phase Chronic Myelogenous Leukemia","enrollment":51},{"nctId":"NCT07091019","phase":"","title":"A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-11-15","conditions":"Chronic Myelogenous Leukemia - Chronic Phase","enrollment":1000},{"nctId":"NCT05722795","phase":"NA","title":"Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2023-06-01","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":40},{"nctId":"NCT03469011","phase":"PHASE1","title":"A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2018-09-18","conditions":"Papillary Thyroid Cancer","enrollment":14},{"nctId":"NCT04129931","phase":"PHASE2","title":"PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2019-12-19","conditions":"Asthma","enrollment":395},{"nctId":"NCT00476190","phase":"PHASE2","title":"ALL Adult Consortium Trial: Adult ALL Trial","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-04","conditions":"Acute Lymphoblastic Leukemia","enrollment":112},{"nctId":"NCT01860456","phase":"","title":"TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2013-05","conditions":"Chronic Myeloid Leukemia","enrollment":412},{"nctId":"NCT01751425","phase":"PHASE1","title":"Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-07-24","conditions":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual Disease","enrollment":8},{"nctId":"NCT05413915","phase":"PHASE3","title":"Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarit Assouline","startDate":"2023-11-01","conditions":"Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, Chronic Myeloid Leukemia in Remission","enrollment":164},{"nctId":"NCT06962254","phase":"PHASE1","title":"Imatinib and Trametinib for KRAS-mutated Solid Tumor","status":"RECRUITING","sponsor":"China Medical University Hospital","startDate":"2025-05-10","conditions":"Solid Tumor Cancer","enrollment":10},{"nctId":"NCT05071482","phase":"PHASE4","title":"Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL","status":"TERMINATED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-09-16","conditions":"Acute Leukemia","enrollment":39},{"nctId":"NCT06061094","phase":"PHASE2","title":"Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT","status":"RECRUITING","sponsor":"Goethe University","startDate":"2023-07-14","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":220},{"nctId":"NCT03632135","phase":"PHASE3","title":"Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Cordgenics, LLC","startDate":"2018-05-20","conditions":"Recurrent Glioblastoma","enrollment":78},{"nctId":"NCT06917196","phase":"","title":"PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2023-12-04","conditions":"Pulmonary Arterial Hypertension (PAH), Lung Fibrosis Interstitial","enrollment":16},{"nctId":"NCT01085617","phase":"","title":"Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University College, London","startDate":"2010-12","conditions":"Leukemia, Mucositis, Oral Complications","enrollment":""},{"nctId":"NCT03844360","phase":"PHASE4","title":"Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease","status":"RECRUITING","sponsor":"Wei Zhao","startDate":"2016-01-31","conditions":"Hematological Neoplasms","enrollment":1500},{"nctId":"NCT02852486","phase":"PHASE2","title":"Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2016-06-22","conditions":"Leukemia, Chronic Myeloid","enrollment":31},{"nctId":"NCT05282108","phase":"","title":"Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia","status":"RECRUITING","sponsor":"Hikma Pharmaceuticals LLC","startDate":"2022-07-20","conditions":"Chronic Myeloid Leukemia","enrollment":240},{"nctId":"NCT06119789","phase":"PHASE2","title":"Precision Cancer Therapy in Rare Cancers","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2025-03-20","conditions":"Rare Malignant Neoplasm","enrollment":96},{"nctId":"NCT01804985","phase":"PHASE2","title":"De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2013-12","conditions":"Chronic Myeloid Leukaemia","enrollment":174},{"nctId":"NCT02413736","phase":"PHASE3","title":"Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST","status":"ACTIVE_NOT_RECRUITING","sponsor":"Heikki Joensuu","startDate":"2015-05","conditions":"Sarcoma","enrollment":255},{"nctId":"NCT03906292","phase":"PHASE2","title":"Frontline Asciminib Combination in Chronic Phase CML","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Jena","startDate":"2019-08-19","conditions":"Chronic Myeloid Leukemia","enrollment":125},{"nctId":"NCT04126681","phase":"PHASE2","title":"A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-10-21","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":144},{"nctId":"NCT06038552","phase":"","title":"Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2002-01-01","conditions":"GIST, Malignant, Liver Metastases","enrollment":238},{"nctId":"NCT02401815","phase":"PHASE1, PHASE2","title":"CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Cogent Biosciences, Inc.","startDate":"2015-03-06","conditions":"Gastrointestinal Stromal Tumors","enrollment":51},{"nctId":"NCT04423185","phase":"PHASE2","title":"PLATFORM Study of Precision Medicine for Rare Tumors","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-08-15","conditions":"Rare Tumor","enrollment":770},{"nctId":"NCT04633122","phase":"PHASE2","title":"A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib","status":"COMPLETED","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2020-11-25","conditions":"Gastrointestinal Stromal Tumor(GIST)","enrollment":108},{"nctId":"NCT04722848","phase":"PHASE3","title":"Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2021-09-08","conditions":"Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL","enrollment":236},{"nctId":"NCT02398825","phase":"PHASE2","title":"Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib","status":"TERMINATED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2016-06-23","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Adults","enrollment":14},{"nctId":"NCT05682924","phase":"","title":"Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib","status":"RECRUITING","sponsor":"Samara State Medical University","startDate":"2022-10-01","conditions":"Chronic Myeloid Leukaemia","enrollment":105},{"nctId":"NCT06219733","phase":"PHASE2","title":"Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)","status":"WITHDRAWN","sponsor":"MedPacto, Inc.","startDate":"2021-06-01","conditions":"Dermoid","enrollment":""},{"nctId":"NCT04147533","phase":"PHASE2","title":"Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masaryk University","startDate":"2020-06-16","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug","enrollment":150},{"nctId":"NCT06692803","phase":"","title":"Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-23","conditions":"Chronic Myeloid Leukemia","enrollment":2043},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT06051409","phase":"PHASE3","title":"A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2023-08-31","conditions":"Ph+ ALL","enrollment":350},{"nctId":"NCT03722420","phase":"PHASE3","title":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2018-12-28","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":238}],"_emaApprovals":[],"_faersSignals":[{"count":11155,"reaction":"DEATH"},{"count":986,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":725,"reaction":"PYREXIA"},{"count":672,"reaction":"CHRONIC MYELOID LEUKAEMIA"},{"count":630,"reaction":"ANAEMIA"},{"count":586,"reaction":"SECOND PRIMARY MALIGNANCY"},{"count":541,"reaction":"GASTROINTESTINAL STROMAL TUMOUR"},{"count":516,"reaction":"VOMITING"},{"count":481,"reaction":"NAUSEA"},{"count":479,"reaction":"DIARRHOEA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL1642"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":452,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Glivec","genericName":"Glivec","companyName":"PETHEMA Foundation","companyId":"pethema-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:18:13.161048+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}